Proactive Investors - Run By Investors For Investors

Scancell Holdings inks drug delivery technology deal

It has exercised an option on TriGrid, which was developed by Ichor Medical Systems
woman at a microscope
The new technology will be used in an upcoming cancer trial

Immunotherapy specialist Scancell Holdings PLC (LON:SCLP) has exercised an option to in-licence delivery technology for its lead drug candidate.

It has inked a deal with Ichor Medical Systems, which has developed the TriGrid 2.0 electroporation system.

READ: Scancell receives European patent protection for immunotherapy platform

TriGrid will now be used in harness with Scancell's SCIB1 vaccine, a melanoma treatment.

Specifically, it will be deployed in an upcoming Phase II clinical trial in which the Scancell drug candidate is being deployed alongside a checkpoint inhibitor.

Vital component 

Chief executive Cliff Holloway said: "Ichor's proprietary TriGrid electroporation delivery system is a vital component for the delivery of our SCIB1 vaccine and in particular, to our upcoming US clinical study of SCIB1 in combination with a checkpoint inhibitor, which is expected to commence later this year.

“The exercise of this commercial option is a further key milestone in bringing this important new treatment to the market."

The company said an option fee will be paid. Ichor will receive further cash once certain developmental milestones are passed.

Scancell has also agreed an extension for the exercise of share options granted to Ichor as part of the initial deal.

View full SCLP profile View Profile

Scancell Holdings PLC Timeline

Related Articles

Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
December 03 2018
Feraccru already has EU approval while in Switzerland the drug can be used for iron deficiency anaemia in adults with inflammatory bowel disease
A doctor's stethoscope and a marijuana plant
February 22 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use